A remarkable 16-amino-acid peptide encoded by your mitochondrial DNA that acts as an 'exercise mimetic'—boosting metabolism, improving insulin sensitivity, and helping your cells adapt to metabolic stress just like a good workout would [1][3].
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Subcutaneous
Route
3 recommended
Sites
Once daily
Frequency
Preparation
Bacteriostatic water (BAC water)—the preservative keeps it safe for multiple uses
Insulin syringes (29-31 gauge)—thin needles mean less discomfort
Alcohol swabs for cleaning vial tops and injection sites
Your MOTS-c powder vial
Pro tip
Prepare all supplies on a clean surface before you begin. Having everything ready makes the process smoother and more sterile.
Mixing
Wash your hands thoroughly with soap and water. Gather all supplies on a clean, flat surface.
Remove the plastic cap from the peptide vial and wipe the rubber stopper with an alcohol swab. Let it air dry.
Draw the appropriate amount of bacteriostatic water into a sterile syringe.
Insert the needle into the vial at an angle, aiming at the inside wall of the vial. Slowly push the plunger to let the water trickle down the glass wall -- do NOT squirt directly onto the powder.
Once all water is added, gently swirl the vial in a slow circular motion. Never shake the vial, as this can damage the peptide bonds.
Continue swirling until the powder is completely dissolved and the solution is clear. If particles remain, let the vial sit for a few minutes and swirl again.
Label the vial with the date of reconstitution, the peptide name, and the concentration (e.g. 250mcg per 0.1mL).
Example calculation
If you have a 10mg vial and add 1mL of BAC water, you get a concentration of 10mg/mL. So every 0.5mL (50 units on an insulin syringe) equals 5mg of MOTS-c.
Dose calculation
For a 5mg dose at 10mg/mL concentration: draw 0.5mL (50 units on a standard insulin syringe). For a 10mg dose: draw 1mL (100 units).
Pro tip
Always add the bacteriostatic water slowly, letting it run down the side of the vial. Never shake the vial -- swirl gently to avoid damaging the peptide.
Location
Site 01
Abdomen
Pinch the skin 2 inches from navel. Avoid the area directly around the belly button. Rotate between left and right sides.
Site 02
Outer Thigh
Middle third of the outer thigh. Keep at least 4 inches above the knee and below the hip. Alternate legs each injection.
Site 03
Upper Arm
Back or outer area of the upper arm. This site may require assistance from another person for proper technique.
Rotate between 3 sites to prevent tissue buildup and ensure consistent absorption.
Pro tip
Rotate your injection sites with each dose to prevent lipohypertrophy (buildup of fatty tissue). Keep a simple log of where you last injected.
Step by step
Wash your hands thoroughly with soap and water
Clean the injection site with an alcohol swab and let it air dry completely
Pinch about an inch of skin to create a fold
Insert the needle at a 45-90 degree angle (45 if you're lean, 90 if you have more tissue)
Push the plunger slowly and steadily
Wait 5 seconds before removing the needle
Apply light pressure if needed—don't rub
Pro tip
This peptide uses subcutaneous injection (just under the skin)—the easiest and most common method for self-administration. Inject at a 45-90 degree angle into pinched skin. Aspirate before injecting to ensure you haven't hit a blood vessel.
Timing
Optimal timing
Best time
Morning injections work best for most people since MOTS-c affects metabolic pathways that are naturally more active earlier in the day. Taking it before or after morning exercise may enhance its effects.
With food?
MOTS-c can be taken regardless of food timing for injections. However, some users prefer taking it fasted.
Stacking notes
If stacking with other peptides, inject them at different sites. MOTS-c pairs well with longevity-focused compounds like Epithalon or NAD+ precursors. If using alongside blood sugar-lowering supplements like berberine, monitor glucose levels carefully.
Sample daily schedule
Morning (6-9 AM, ideally before or after light exercise)
5-15 mg depending on protocol injection
Site: Rotate between belly, thigh, and arm
Morning timing aligns with your body's natural metabolic cycles when AMPK activity and insulin sensitivity are optimized. Follow a 4-6 week cycle, then take 2-4 weeks off before repeating.
Dosing tiers
Dose
5 mg
Frequency
2-3 times per week
Duration
4-week cycle
Lower end of the research/practice range; MOTS-c is a mitochondrial-derived peptide that activates AMPK [1][2]. No completed human clinical trial dosing exists; figures reflect documented research practice.
Dose
10 mg
Frequency
2-3 times per week
Duration
4-8 week cycle, then washout
Upper end of the commonly used research/practice range, cycled with a washout period.
Preservation
Before mixing
Keep your MOTS-c powder in the refrigerator (36-46°F / 2-8°C) for short-term storage or in the freezer (-4°F / -20°C) for long-term storage. Store in the original sealed vial away from light. Properly stored powder can remain stable for 2+ years when frozen.
After mixing
Once mixed with bacteriostatic water, refrigerate at 36-46°F (2-8°C). Never freeze the reconstituted solution—freezing destroys the peptide. Keep away from light and use within 21-28 days.
Shelf life after mixing
21-28 days
Signs of degradation
Discard the vial immediately if you notice any of these:
Cloudy or hazy appearance (should be crystal clear)
Visible particles floating or settled at the bottom
Color changes—any yellowing or discoloration means toss it
Unusual smell—fresh solution should have little to no odor
Important
When to stop
Any signs of allergic reaction—stop immediately and seek medical help
Persistent fatigue that doesn't improve after the first week
Recurrent hypoglycemia symptoms, especially if you're diabetic
Injection site reactions that spread or don't heal
Any side effect that feels serious or really concerns you
Your research protocol/cycle is complete
MOTS-c is a research compound, not an FDA-approved medication. Never start, stop, or change your dosing without guidance from a qualified healthcare provider. This information is for educational purposes only—not medical advice.
Clean technique checklist
Wash hands thoroughly with soap and water before handling supplies
Swab vial tops and injection site with alcohol and let dry
Never touch the needle tip or allow it to contact non-sterile surfaces
Use a new syringe and needle for each injection
Dispose of used sharps in a proper sharps container
Store reconstituted peptides according to the storage instructions above
Published research
Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P · 2015
This groundbreaking discovery paper identified MOTS-c as a new hormone encoded in mitochondrial DNA. The researchers showed that MOTS-c targets skeletal muscle, activates AMPK, and prevents both age-dependent and diet-induced insulin resistance and obesity in mice—establishing it as a genuine metabolic regulator.
Lee C, Kim KH, Cohen P · 2016
This review confirmed MOTS-c's role as a 'mitochondrial hormone' with far-reaching effects. It explained how MOTS-c inhibits the folate cycle and purine biosynthesis, leading to AMPK activation—making it a potential therapeutic target for obesity, diabetes, and aging-related metabolic decline.
Feng Y, Rao Z, Tian X, Hu Y, Yue L, Meng Y, Zhong Q, Chen W, Xu W, Li H, Hu Y, Shi R · 2024
This study in marathon runners and mice revealed that MOTS-c levels closely correlate with aerobic exercise capacity. Endurance training boosts MOTS-c secretion, which enhances mitochondrial function through AMPK/PGC-1α activation—suggesting MOTS-c mediates some of exercise's metabolic benefits.
Kumagai H, Kim SJ, Miller B, et al. · 2024
Researchers discovered that MOTS-c directly binds and activates the CK2 enzyme, which is required for its muscle-protective effects. The study also found that a natural MOTS-c variant (K14Q) with reduced CK2 binding is associated with higher sarcopenia and type 2 diabetes risk—providing the first genetic link between MOTS-c and human metabolic disease.
Gudiksen A, Hansen CC, van der Stede T, et al. · 2026
This study demonstrated that MOTS-c administration improves mitochondrial bioenergetic performance in skeletal muscle through PGC-1α and AMPK pathways. Importantly, it reduced mitochondrial reactive oxygen species and oxidative damage, showing MOTS-c protects cells from the harmful byproducts of energy production.
Kim KH, Son JM, Benayoun BA, Lee C · 2018
In cultured cells, MOTS-c moved from the mitochondria into the nucleus within about 30 minutes of metabolic stress such as glucose restriction, serum removal, or oxidative stress, and this movement depended on AMPK. Once in the nucleus, MOTS-c bound antioxidant response element (ARE) sequences in genes including HO-1 and NQO1 and interacted with the stress-response transcription factor NRF2, increasing expression of those genes.
D'Souza RF, Woodhead JST, Hedges CP, Zeng N, Wan J, Kumagai H, Lee C, Cohen P, Cameron-Smith D, Mitchell CJ, Merry TL · 2020
In healthy men, circulating MOTS-c was 11% lower in middle-aged men (45-55 y) and 21% lower in older men (70-81 y) than in young men (18-30 y), and the age effect remained statistically significant after adjusting for body composition and metabolic measures. Skeletal muscle MOTS-c moved in the opposite direction, being roughly 1.5-fold higher in the older groups, and plasma MOTS-c was not correlated with HOMA-IR.
Yang L, Li M, Liu Y, Bai Y, Yin T, Chen Y, Jiang J, Liu S · 2024
Alongside its main findings on pain behaviour, this mouse study assessed organ safety after long-term intraperitoneal MOTS-c dosing. Chronic administration had little effect on liver, renal, lipid, or cardiac function measures, and no differences in histological damage to liver, spleen, or kidney were seen between treated and control groups.
LaMoia TE, Shulman GI · 2021
This review states that metformin's glucose-lowering effect in people with poorly controlled type 2 diabetes comes primarily from inhibiting hepatic glucose production, and reviews the clinical studies in patients that confirmed this. It also traces metformin's clinical history from its 1957 introduction by Jean Sterne through FDA approval in 1994.
U.S. Food and Drug Administration, CDER (Li J, Poon N-L, Asante K, Albuquerque E, Benedict A, San Antonio M, Kasim S) · 2026
FDA review (dated 5/11/2026) of MOTS-c (free base) and MOTS-c acetate for the 503A bulks list. States there is no USP/NF monograph and neither is a component of an FDA-approved drug; FDA did not identify clinical studies evaluating the proposed uses, found no published studies in which MOTS-c products were used in humans, and did not identify any clinical studies or human exposure data for MOTS-c via any route, so potential safety risks in humans are unknown. FAERS searches through March 9, 2025 retrieved no adverse-event reports. Nonclinical pharmacology is limited to in-vitro and rodent models without dose-response assessment, and FDA did not identify nonclinical toxicity studies. Raises immunogenicity concern for subcutaneous peptide injection. The nominated products were 5 mg and 10 mg for subcutaneous injection. Notes MOTS-c is listed as prohibited in Global DRO from the 2024 WADA Prohibited List. FDA proposed not adding MOTS-c or MOTS-c acetate to the 503A Bulks List.
Head to head